{"nctId":"NCT00293540","briefTitle":"Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer","startDateStruct":{"date":"2006-02"},"conditions":["Breast Cancer"],"count":249,"armGroups":[{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: oophorectomy","Drug: Tamoxifen"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Procedure: oophorectomy","Drug: Tamoxifen"]}],"interventions":[{"name":"oophorectomy","otherNames":[]},{"name":"Tamoxifen","otherNames":["Nolvadex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Estrogen receptor or progesterone receptor positive breast cancer\n* Premenopausal with regular menstrual cycles\n\nExclusion Criteria:\n\n* Current oral contraceptives","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Assess whether patients who undergo surgical oophorectomy in the history-estimated mid-luteal phase of their menstrual cycles survive longer than patients who undergo this surgery in the history-estimated mid-follicular phase of their menstrual cycles.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"2.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":115},"commonTop":[]}}}